| Title |
Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care
|
|---|---|
| Published in |
Psychopharmacology, May 2013
|
| DOI | 10.1007/s00213-013-3140-7 |
| Pubmed ID | |
| Authors |
Macey L. Murray, Yingfen Hsia, Karen Glaser, Emily Simonoff, Declan G. M. Murphy, Philip J. Asherson, Hanna Eklund, Ian C. K. Wong |
| Abstract |
Autism spectrum disorders (ASDs) affect 1 % of children, having significant impact on health and social outcomes. Psychotropic medication use by individuals with ASD in the USA increased over time, and polypharmacy occurred in >50 % of those prescribed. In the UK, no psychotropic drugs are approved in ASDs, and little is known about patterns of pharmacological treatment in the ASD population and associated co-morbidities. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 24% |
| Spain | 2 | 10% |
| Egypt | 1 | 5% |
| Germany | 1 | 5% |
| United Kingdom | 1 | 5% |
| Canada | 1 | 5% |
| Unknown | 10 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 76% |
| Scientists | 3 | 14% |
| Practitioners (doctors, other healthcare professionals) | 2 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 330 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | <1% |
| Germany | 1 | <1% |
| France | 1 | <1% |
| Brazil | 1 | <1% |
| Argentina | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 323 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 67 | 20% |
| Researcher | 50 | 15% |
| Student > Ph. D. Student | 43 | 13% |
| Student > Bachelor | 29 | 9% |
| Student > Doctoral Student | 18 | 5% |
| Other | 52 | 16% |
| Unknown | 71 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 73 | 22% |
| Medicine and Dentistry | 64 | 19% |
| Neuroscience | 18 | 5% |
| Nursing and Health Professions | 17 | 5% |
| Social Sciences | 16 | 5% |
| Other | 53 | 16% |
| Unknown | 89 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2018.
All research outputs
#1,503,249
of 25,654,806 outputs
Outputs from Psychopharmacology
#357
of 5,352 outputs
Outputs of similar age
#12,117
of 209,371 outputs
Outputs of similar age from Psychopharmacology
#3
of 57 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,352 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,371 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.